UroGen Pharma URGN Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$153.49M-21.0% | -$126.87M-24.1% | -$102.24M+6.9% | -$109.78M+0.9% | ||
| $347K-11.3% | $391K-51.5% | $807K-5.2% | $851K+5.8% | ||
| $11.96M-8.8% | $13.11M+40.3% | $9.34M-11.7% | $10.58M-54.2% | ||
| -$162.44M-67.9% | -$96.77M-26.7% | -$76.38M+12.8% | -$87.56M-3.1% | ||
| $289K-2.0% | $295K+52.1% | $194K-23.6% | $254K-66.2% | ||
| $61.56M— | —— | -$953K— | —— | ||
| —— | $24.49M— | $0— | —— | ||
| $39.92M-79.5% | $194.62M+66.4% | $116.93M+20.3% | $97.21M— | ||
| —— | —— | —— | —— | ||
| -$162.73M-67.7% | -$97.06M-26.8% | -$76.57M+12.8% | -$87.81M-2.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does UroGen Pharma's cash flow data come from?
- Every line is extracted from UroGen Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.